Compounds > dh 990
Page last updated: 2024-11-06

dh 990

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DH 990: RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID40826
CHEMBL ID3248314
SCHEMBL ID11601063
MeSH IDM0059871

Synonyms (23)

Synonym
hexanoic acid, 2-(4-hydroxy-3,5-di-tert-butylphenylthio)-
2-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)thio)-hexanoic acid
mdl-29350
2-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)thio)hexanoic acid
dh 990
2-(4-hydroxy-3,5-di-tert-butylphenylthio)-hexanoic acid
hexanoic acid, 2-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)thio)-
brn 2159986
dl 990
dh-990
dl-990
53602-61-2
l03f8q088h ,
unii-l03f8q088h
CHEMBL3248314
CQGSORMFKDTILR-UHFFFAOYSA-N
2-((3,5-di-tert-butyl-4-hydroxyphenyl)thio)hexanoic acid
SCHEMBL11601063
2-(3,5-ditertiary butyl-4-hydroxyphenyl)-thio-hexanoic acid
2-(3,5-di-t-butyl-4-hydroxy-phenylthio)-hexanoic acid
DTXSID00968373
2-[(3,5-di-tert-butyl-4-hydroxyphenyl)thio]hexanoic acid
Q27282535
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1134514Hypolipidemic activity in Sprague-Dawley rat assessed as reduction in serum cholesterol level at 0.06 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1134503Hypolipidemic activity in Sprague-Dawley rat assessed as reduction in serum cholesterol level at 0.25 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1134513Retardation factor of the compound by thin layer chromatography1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1134505Hypolipidemic activity in Sprague-Dawley rat assessed as reduction in serum triglyceride level at 0.25 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1134504Hypolipidemic activity in Sprague-Dawley rat assessed as reduction in serum cholesterol level at 0.125 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1134506Hypolipidemic activity in Sprague-Dawley rat assessed as reduction in serum triglyceride level at 0.125 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1134512Toxicity in rat1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1134507Toxicity in Sprague-Dawley rat assessed as increase in liver weight at 0.25 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1134516Hypolipidemic activity in Sprague-Dawley rat assessed as reduction in serum triglyceride level at 0.06 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1134511Toxicity in mouse1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1134509Hypolipidemic activity in Sprague-Dawley rat assessed as reduction in serum cholesterol level at 0.03 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1134515Hypolipidemic activity in Sprague-Dawley rat assessed as reduction in serum triglyceride level at 0.03 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1134508Toxicity in Sprague-Dawley rat assessed as increase in liver weight at 0.125 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (62.50)18.7374
1990's3 (37.50)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.18 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ethanolamine
[no description available]		1.9810ethanolamines;
primary alcohol;
primary amine		Escherichia coli metabolite;
human metabolite;
mouse metabolite
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		1.9510aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
meclofenoxate
Meclofenoxate: An ester of DIMETHYLAMINOETHANOL and para-chlorophenoxyacetic acid.		1.9610monocarboxylic acid
probucol
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.		1.9510dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
pirinixic acid
pirinixic acid: structure		2.3720aryl sulfide;
organochlorine compound;
pyrimidines
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		1.9810L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cytidine diphosphate
Cytidine Diphosphate: Cytidine 5'-(trihydrogen diphosphate). A cytosine nucleotide containing two phosphate groups esterified to the sugar moiety. Synonyms: CRPP; cytidine pyrophosphate.		1.9710cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-diphosphate		Escherichia coli metabolite;
mouse metabolite
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		1.9810aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
tubercidin
Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.		1.9810antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
3-deazaadenosine
3-deazaadenosine: RN given refers to parent cpd.		1.9810
lifibrate
lifibrate: hypolipemic, hypocholesteremic agent; minor descriptor (75-82); online & Index Medicus search GLYCOLATES (75-82)		1.9610
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		1.9610benzenes;
phenyl acetates
cdp ethanolamine
[no description available]		1.9710nucleotide-(amino alcohol)s;
phosphoethanolamine		mouse metabolite
oleic acid
Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.		2.3720octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
linoleic acid
Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.		1.9610octadecadienoic acid;
omega-6 fatty acid		algal metabolite;
Daphnia galeata metabolite;
plant metabolite
lysophosphatidylcholines
lysophosphatidylcholine : An acylglycerophosphocholine resulting from partial hydrolysis of a phosphatidylcholine, which removes one of the fatty acyl groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.		1.96101-O-acyl-sn-glycero-3-phosphocholine
oleoyl-coenzyme a
oleoyl-coenzyme A: RN given refers to (Z)-isomer		2.3720octadecenoyl-CoAEscherichia coli metabolite;
mouse metabolite
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		1.98101,2-diacyl-sn-glycero-3-phosphocholine
ConditionIndicatedRelationship StrengthStudiesTrials
Choline Deficiency
A condition produced by a deficiency of CHOLINE in animals. Choline is known as a lipotropic agent because it has been shown to promote the transport of excess fat from the liver under certain conditions in laboratory animals. Combined deficiency of choline (included in the B vitamin complex) and all other methyl group donors causes liver cirrhosis in some animals. Unlike compounds normally considered as vitamins, choline does not serve as a cofactor in enzymatic reactions. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)		01.9810
Hepatocellular Carcinoma
[description not available]		01.9810
Cancer of Liver
[description not available]		01.9810
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		01.9810
Liver Neoplasms
Tumors or cancer of the LIVER.		01.9810